Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | JAK3 | P52333 | 16/20 | 0.47 |
| ▸ | SYK | P43405 | 3/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | JAK1 | P23458 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12372398 | 0.85 | MAPK1 (0.44) | MAPK1JAK3SYKJAK2JAK1 | |
| SCHEMBL2281069 | 0.84 | JAK3 (0.47) | JAK3SYKJAK2JAK1 | |
| SCHEMBL14737008 | 0.83 | SYK (0.61) | SYK | |
| SCHEMBL652080 | 0.82 | JAK3 (0.47) | JAK3SYKJAK2JAK1 | |
| SCHEMBL12402568 | 0.82 | JAK3 (0.47) | JAK3SYKJAK2JAK1 | |
| SCHEMBL2344126 | 0.82 | JAK3 (0.49) | JAK3SYKJAK2JAK1 | |
| SCHEMBL2274744 | 0.82 | MAPK1 (0.42) | MAPK1JAK3SYKJAK2JAK1 | |
| SCHEMBL14655543 | 0.81 | MAPK1 (0.56) | MAPK1JAK3SYKJAK2JAK1 | |
| SCHEMBL31070091 | 0.81 | MAPK1 (0.56) | MAPK1JAK3SYKJAK2JAK1 | |
| SCHEMBL651335 | 0.81 | JAK3 (0.46) | JAK3SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8119636-B2 | Pyrrolopyrazine kinase inhibitors | ROCHE PALO ALTO LLC (US) | 2012-02-21 | — | — | US | claimed |
| EP-2247593-B1 | PYRROLOPYRAZINE KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2011-08-10 | — | — | EP | claimed |
| EP-2247593-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2010-11-10 | — | — | EP | claimed |
| WO-2009106444-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-09-03 | — | — | WO | claimed |
| US-20090215785-A1 | Pyrrolopyrazine kinase inhibitors | ROCHE PALO ALTO LLC | 2009-08-27 | — | — | US | claimed |
| US-9676778-B2 | Substituted pyrrolo[2,3-b]pyrazines as JAK3 inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2017-06-13 | — | — | US | disclosed |
| EP-2922538-B1 | AZAINDOLE DERIVATIVES AS JAK3 INHIBITORS | PRINCIPIA BIOPHARMA INC (US) | 2016-10-19 | — | — | EP | disclosed |
| US-9187487-B2 | Azaindole derivatives as tyrosine kinase inhibitors | PRINCIPIA BIOPHARMA, INC. (US) | 2015-11-17 | — | — | US | disclosed |
| US-20150291600-A1 | AZAINDOLE DERIVATIVES AS JAK3 INHIBITORS | PRINCIPIA BIOPHARMA INC. | 2015-10-15 | — | — | US | disclosed |
| EP-2922538-A1 | AZAINDOLE DERIVATIVES AS JAK3 INHIBITORS | Principia Biopharma Inc. (US) | 2015-09-30 | — | — | EP | disclosed |
| WO-2014081732-A1 | AZAINDOLE DERIVATIVES AS JAK3 INHIBITORS | PRINCIPIA BIOPHARMA INC. (US) | 2014-05-30 | — | — | WO | disclosed |
| US-20140073626-A1 | AZAINDOLE DERIVATIVES AS TYROSINE KINASE INHIBITORS | Principia Biopharma (US) | 2014-03-13 | — | — | US | disclosed |
| US-20090215750-A1 | Pyrrolopyrazine kinase inhibitors | ROCHE PALO ALTO LLC | 2009-08-27 | — | — | US | disclosed |
| US-20090215750-A1 | Pyrrolopyrazine kinase inhibitors | ROCHE PALO ALTO LLC | 2009-08-27 | — | — | US | disclosed |
| US-20090215750-A1 | Pyrrolopyrazine kinase inhibitors | ROCHE PALO ALTO LLC | 2009-08-27 | — | — | US | disclosed |
| US-20090215724-A1 | Pyrrolopyrazine kinase inhibitors | ROCHE PALO ALTO LLC | 2009-08-27 | — | — | US | disclosed |
| US-20090215788-A1 | Pyrrolopyrazine kinase inhibitors | ROCHE PALO ALTO LLC | 2009-08-27 | — | — | US | disclosed |
| US-20090215724-A1 | Pyrrolopyrazine kinase inhibitors | ROCHE PALO ALTO LLC | 2009-08-27 | — | — | US | disclosed |
| US-20090215724-A1 | Pyrrolopyrazine kinase inhibitors | ROCHE PALO ALTO LLC | 2009-08-27 | — | — | US | disclosed |
| US-20090215785-A1 | Pyrrolopyrazine kinase inhibitors | ROCHE PALO ALTO LLC | 2009-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140073626-A1 | AZAINDOLE DERIVATIVES AS TYROSINE KINASE INHIBITORS | BMX, BLK, ITK | MAPK1 559/4885JAK3 4/4885SYK 43/4885 |
| US-20090215750-A1 | Pyrrolopyrazine kinase inhibitors | SYK, ZAP70, JAK2 | MAPK1 431/4885JAK3 7/4885SYK 1/4885 |
| US-20090215788-A1 | Pyrrolopyrazine kinase inhibitors | SYK, ZAP70, JAK2 | MAPK1 431/4885JAK3 7/4885SYK 1/4885 |
| US-20150291600-A1 | AZAINDOLE DERIVATIVES AS JAK3 INHIBITORS | JAK3, JAK2, JAK1 | MAPK1 663/4885JAK3 1/4885SYK 130/4885 |
| US-20090215724-A1 | Pyrrolopyrazine kinase inhibitors | SYK, ZAP70, JAK1 | MAPK1 376/4885JAK3 7/4885SYK 1/4885 |
| US-20090215785-A1 | Pyrrolopyrazine kinase inhibitors | SYK, ZAP70, JAK2 | MAPK1 431/4885JAK3 7/4885SYK 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.